Citation Impact
Citing Papers
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates
2005
Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331
2000
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
2002 Standout
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression
2003
Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells
1996
Separation methods for methotrexate, its structural analogues and metabolites
2001
Molecular mechanisms of drug resistance
2005
Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)
1998
Cancer drug resistance: an evolving paradigm
2013 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
A review of stimuli-responsive nanocarriers for drug and gene delivery
2008 Standout
‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia
1995
Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells
1994
A phase II study
2000
Modification of cell proliferation with inhibitors
1992
Resistance to antifolates
2003
Dendrimers in biomedical applications—reflections on the field
2005 Standout
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines
2002
Targeting multidrug resistance in cancer
2006 Standout
Magnetic nanoparticles in MR imaging and drug delivery
2008 Standout
Karnofsky memorial lecture. Ode to methotrexate.
1993
Analysis of anticancer drugs: A review
2011 Standout
Column-switching high-performance liquid chromatographic method for the determination of a thymidylate synthase inhibitor, LY231514, an investigational agent for the treatment of solid tumors, in human plasma
1994
Determination of raltitrexed in human plasma by high performance liquid chromatography–electrospray ionization-mass spectrometry
2007
5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods
2002 Standout
Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil
1995
Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production
2008 Standout
The methotrexate story: A paradigm for development of cancer chemotherapeutic agents
1994
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells
2008
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
2002
Cell cycle control and cancer chemotherapy
1994 StandoutNobel
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay
2005 Standout
Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications
1994
Final results of a randomised trial comparing ‘Tomudex’® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
1996
Folate status and the safety profile of antifolates
2002
Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems.
1991
Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design
1997 Standout
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates.
2002
Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials.
2001
Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
1990
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.
1999
Carboxylic acid bioisosteres of γ-linked dipeptide analogues of the folate-based thymidylate synthase (TS) inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)
1996
Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models
2000 Standout
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates
2000
Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
2001
Theoretical Studies Suggest a New Antifolate as a More Potent Inhibitor of Thymidylate Synthase
2000
Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates
2015
Mechanisms of Cancer Drug Resistance
2002 Standout
Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine
2010
Chemotherapy for the Treatment of Patients with Metastatic Colorectal Cancer: An Overview
1997
Insertion of an intracisternal A particle within the 5'-regulatory region of a gene encoding folate-binding protein in L1210 leukemia cells in response to low folate selection. Association with increased protein expression.
1992 StandoutNobel
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
1997
Antifolate Activity of Epigallocatechin Gallate against Stenotrophomonas maltophilia
2005 Standout
A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis
1989
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer
2003 Standout
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection.
1998 StandoutNobel
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Design and Synthesis of Potent Non-Polyglutamatable Quinazoline Antifolate Thymidylate Synthase Inhibitors
1999
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
2004 Standout
DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSα/hMutSβ ratio and reduces the efficiency of base–base mismatch repair
1997 StandoutNobel
5‐Substituted 1H‐Tetrazoles as Carboxylic Acid Isosteres: Medicinal Chemistry and Synthetic Methods
2003 Standout
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Prescribed drugs containing nitrogen heterocycles: an overview
2020 Standout
Works of A.L. Jackman being referenced
Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694
1995
Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models
1998
Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action
1998
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines
1995
Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
2000
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines
1995
Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
1990
2-AMINO-4-HYDROXY QUINAZOLINE ANALOGS OF FOLIC-ACID AS THYMIDYLATE SYNTHETASE INHIBITORS
1979
Analysis of thymidylate synthase gene amplification and of mRNA levels in the cell cycle.
1987
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).
1987
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
1986
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
1991